Stay updated on Blinatumomab & Pembrolizumab in B-ALL Clinical Trial
Sign up to get notified when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.

Latest updates to the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation regarding improved survival with ipilimumab in patients with metastatic melanoma, which may affect the credibility of the information presented.SummaryDifference0.8%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoChange DetectedDifference0.5%
- Check22 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study descriptions for a Phase I/II trial involving blinatumomab and pembrolizumab for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Additionally, the page now includes new collaborators and a revision update.SummaryDifference36%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.6%
- Check37 days agoChange DetectedThe page has been updated to reflect a change in focus from Acute Graft Versus Host Disease to Acute Lymphoblastic Leukemia, along with an update in the version number from v2.14.2 to v2.14.3.SummaryDifference0.4%
Stay in the know with updates to Blinatumomab & Pembrolizumab in B-ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Blinatumomab & Pembrolizumab in B-ALL Clinical Trial page.